---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-025388"
form_type: "8-K"
ticker: "JNJ"
cik: "0000200406"
company_name: "JOHNSON & JOHNSON"
filed_at: "2023-07-24T23:59:59+00:00"
generated_at: "2026-06-13T04:34:09.022530+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# JNJ Q2 preliminary: sales $25.53B (+6.3%), EPS $1.96 (+8.9%)

## Summary
- Net earnings $5.14B vs $4.81B; diluted EPS $1.96 vs $1.80 YoY.
- MedTech sales $7.79B (+12.9%) driven by Abiomed and Electrophysiology growth.
- Pharmaceutical sales $13.73B (+3.1%); DARZALEX +22.4%, TREMFYA +18.3%, CARVYKTI $117M.
- Consumer Health sales $4.01B (+5.4%); OTC +12.0%, Skin Health/Beauty +2.0%.
- Preliminary results subject to adjustment; six-month net earnings fell 49.1% due to $7.2B other expense (Kenvue).

## SEC filing metadata
- accession: 0001628280-23-025388
- form_type: 8-K
- ticker: JNJ
- cik: 0000200406
- company_name: JOHNSON & JOHNSON
- filed_at: 2023-07-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/200406/000162828023025388/0001628280-23-025388-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/200406/000162828023025388/jnj-20230724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-025388
- JSON: https://secwatch.observer/filing/0001628280-23-025388.json
- Plain text: https://secwatch.observer/filing/0001628280-23-025388.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.